-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Kura Oncology (NASDAQ:KURA) Earns Buy Rating From Analysts at Stifel Nicolaus
Kura Oncology (NASDAQ:KURA) Earns Buy Rating From Analysts at Stifel Nicolaus
Analysts at Stifel Nicolaus initiated coverage on shares of Kura Oncology (NASDAQ:KURA – Get Rating) in a research report issued to clients and investors on Monday, The Fly reports. The firm set a "buy" rating on the stock.
Separately, StockNews.com initiated coverage on Kura Oncology in a research note on Wednesday, October 12th. They set a "sell" rating on the stock. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $32.40.
Get Kura Oncology alerts:Kura Oncology Stock Down 3.7 %
NASDAQ KURA traded down $0.50 during trading hours on Monday, hitting $13.14. 364,475 shares of the company were exchanged, compared to its average volume of 760,657. The stock has a 50-day moving average price of $13.58 and a 200 day moving average price of $14.51. Kura Oncology has a 52 week low of $10.41 and a 52 week high of $19.93. The stock has a market cap of $879.07 million, a PE ratio of -6.47 and a beta of 0.90.
Kura Oncology (NASDAQ:KURA – Get Rating) last issued its quarterly earnings data on Thursday, November 3rd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.04. As a group, sell-side analysts anticipate that Kura Oncology will post -2.12 earnings per share for the current year.Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. Great West Life Assurance Co. Can purchased a new position in shares of Kura Oncology during the third quarter valued at approximately $39,000. Nisa Investment Advisors LLC boosted its holdings in shares of Kura Oncology by 80.8% in the second quarter. Nisa Investment Advisors LLC now owns 3,290 shares of the company's stock valued at $60,000 after purchasing an additional 1,470 shares during the period. Amalgamated Bank purchased a new stake in shares of Kura Oncology in the first quarter valued at approximately $123,000. Annandale Capital LLC purchased a new stake in shares of Kura Oncology in the third quarter valued at approximately $137,000. Finally, Bridgefront Capital LLC purchased a new stake in shares of Kura Oncology in the first quarter valued at approximately $180,000.
Kura Oncology Company Profile
(Get Rating)
Kura Oncology, Inc operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias.
See Also
- Get a free copy of the StockNews.com research report on Kura Oncology (KURA)
- Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
- SoFi Technologies Smashes Earnings but Beware the Fed Decision
- Buying The Dip In Colgate-Palmolive
- Mullen Automotive On Hiring Spree, What Could That Mean?
- InterDigital Raises Its Earnings Guidance
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
Stifel Nicolaus的分析师发起了对库拉肿瘤学(纳斯达克:库拉-获得评级)在周一发布给客户和投资者的一份研究报告中,苍蝇报告说。该公司对该股设定了“买入”评级。
另外,StockNews.com在10月12日星期三的一份研究报告中开始了对Kura Oncology的报道。他们对该股设定了“卖出”评级。一名研究分析师对该股的评级为卖出,六名分析师对该公司股票的评级为买入。根据MarketBeat的数据,该股的平均评级为“中等买入”,平均目标价为32.40美元。
到达库拉肿瘤学警报:库拉肿瘤学股票下跌3.7%
周一交易时段,纳斯达克库拉股价下跌0.5美元,至13.14美元。该公司成交量为364,475股,而其平均成交量为760,657股。该股的50日移动均线价格为13.58美元,200日移动均线价格为14.51美元。Kura Oncology的52周低点为10.41美元,52周高点为19.93美元。该股市值为8.7907亿美元,市盈率为-6.47,贝塔系数为0.90。
库拉肿瘤学(纳斯达克代码:Kura-Get Rating)最近一次发布季度收益数据是在11月3日星期四。该公司公布了本季度每股收益(0.53美元),比普遍预期的(0.57美元)高出0.04美元。作为一个整体,卖方分析师预计Kura Oncology本年度每股收益将达到2.12美元。机构资金流入和流出
大型投资者最近调整了对该公司的持股。大西部人寿保险公司在第三季度购买了Kura Oncology的新头寸,价值约3.9万美元。NISA Investment Advisors LLC在第二季度增持了80.8%的Kura Oncology股票。NISA Investment Advisors LLC在此期间又购买了1,470股,现在拥有3290股该公司股票,价值6万美元。合并银行在第一季度购买了Kura Oncology的新股份,价值约12.3万美元。Annandale Capital LLC在第三季度购买了Kura Oncology的新股份,价值约13.7万美元。最后,BridgeFront Capital LLC在第一季度购买了Kura Oncology的新股份,价值约18万美元。
库拉肿瘤学公司简介
(获取评级)
库拉肿瘤公司是一家临床阶段的生物制药公司,从事癌症治疗药物的研究和开发。它的产品线包括治疗HRAS突变实体肿瘤和慢性粒单核细胞白血病的法尼基转移酶抑制剂Tipifarnib,用于MAPK通路肿瘤的ERK抑制剂KO-947,以及用于急性白血病的Menin MLL抑制剂KO-539。
另请参阅
- 免费获取StockNews.com关于Kura肿瘤学的研究报告(Kura)
- 为什么黄金现在可以成为你投资组合中的闪闪发光的一部分
- 索菲技术公司盈利惨淡,但要警惕美联储的决定
- 购买高露洁棕榄中的Dip
- 马伦汽车(Mullen Automotive)大举招聘,这可能意味着什么?
- InterDigital上调盈利指引
接受《库拉肿瘤学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Kura Oncology和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧